Beyond DNA cross-linking: History and prospects of DNA-targeted cancer treatment - Fifteenth Bruce F. Cain Memorial Award Lecture

Cancer Research

Volumn 56, Issue 24, 1996, Pages 5533-5546

  Kohn, Kurt W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMETHINE; COMPLEMENTARY DNA; DNA; DNA TOPOISOMERASE;

CANCER CHEMOTHERAPY; CYTOLOGY; CYTOTOXICITY; DNA CROSS LINKING; DNA DAMAGE; DNA REPAIR; HODGKIN DISEASE; HUMAN; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; REVIEW; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL CYCLE; CROSS-LINKING REAGENTS; DNA; DNA DAMAGE; DNA REPAIR; DNA TOPOISOMERASES, TYPE II; FORECASTING; HISTORY, 20TH CENTURY; HUMANS; PAINTINGS;

EID: 0029731177     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (205)

1. Kohn, K W. DNA filter elution: a window on DNA damage in mammalian cells BioEssays, 18: 505-514, 1996
2. Krumbhaar, E. B. Bone marrow changes in mustard gas poisoning. J. Am Med. Assoc., 73: 715, 1919
3. Marshall, E. K., Jr, Lynch, V , and Smith, H. W. On dichloroethylsulphide, the systemic effects and mechanism of action. J. Pharmcol. Exp. Ther., 12: 291, 1918.
4. Smith, H. W., Clowes, G H. A., and Marshall, E. K , Jr On dichloroethylsulphide, the mechanism of absorption by the skin. J. Pharmacol. Exp. Ther., 13, 1, 1919
5. Lillie, R. S., Clowes, G. H. A., and Chambers, R. On the penetration of dichloroethylsulphide (mustard gas) into marine organisms, and the mechanism of its destructive action on protoplasm. J. Pharmacol. Exp Ther., 14: 75-120, 1919.
6. Krumbhaar, E. B. Role of the blood and the bone marrow in certain forms of gas poisoning. J. Am. Med. Assoc., 72, 39-41, 1919.
7. Krumbhaar, E B , and Krumbhaar, H. D The blood and bone marrow in Yellow Cross gas (mustard gas) poisoning. J. Med. Res , 40: 497-506, 1919.
8. Pappenheimer, A. M., and Vance, M. The effects of intravenous injections of dichloroethylsulfide in rabbits, with special reference to its leukotoxic action. J. Exp. Med., 31: 71-94, 1920.
9. Hektoen, L., and Corper, H. J. The effects of mustard gas (dichlorethyl sulphid) on antibody formation J. Infect. Dis., 28: 279-285, 1921.
10. Magne, H., and Remy, P. Les actions toxiques elementaires de quelques corps generateurs d'acide chlorhydrique par hydrolyse. Bull. Soc. Chim. Biol., 19: 1092-1104, 1937
11. Adair, F. E., and Bagg, H. J. Experimental and clinical studies on the treatment of cancer by dichlorethylsulphide (mustard gas). Ann. Surg., 93: 190-199, 1931.
12. Kabelik, J. Experiences chimiotherapiques sur le carcinome d'Ehrlich de la souris. Compt. Rend Soc. Biol., 110: 394-397, 1932.
13. Visser, J., and de Vos, J. J. Over den invloed van mosterdgas op kwaadaardige gezwellen. Geneesk. Tijdschr. Nederlandsch-Indie., 75, 1363-1380, 1935.
14. Infield, G. B. Disaster at Bari New York Macmillan, 1971.
15. Gilman, A., and Philips, F. S. The biological actions and therapeutic applications of the β-chloroethyl amines and sulfides. Science (Washington DC), 103: 409-415, 1946.
16. Goodman, L S., Wintrobe, M M., Dameshek, W., Goodman, M. J., and Gilman, A. Nitrogen mustard therapy. Use of methyl-bis(beta-chloroethylamine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders J. Am. Med. Assoc., 132: 126-132, 1946.
17. Wilkinson, J. F., and Fletcher, F. Effects of β-chlorethylamine hydrochlorides in leukemia, Hodgkin's disease, and polycythemia vera. Lancet, 1946: 540-545, 1947.
18. Rhodes, C. P. Nitrogen mustards in the treatment of neoplastic disease J. Am. Med. Assoc., 131 656-658, 1946.
19. Auerbach, C., Robson, J. M , and Carr, J. G. The chemical production of mutations. Science (Washington DC), 105: 243-247, 1947.
20. Elmore, D. T., Gulland, J. M., Jordan, D. O., and Taylor, H. F W. The reaction of nucleic acids with mustard gas. Biochem. J , 42: 308-315, 1948
21. Beattie, J. W., and Howell, L. H. Biological actions and therapeutic applications of nitrogen mustard. Q J. Med., New Series., 23: 231-254, 1954.
22. Fruton, J S., Stein, W. H., and Bergmann, M. Chemical reactions of the nitrogen mustard gases. V. The reactions of the nitrogen mustard gases with protein constituents J. Org. Chem., 11, 559-570, 1946
23. Goldacre, R. J., Loveless, A., and Ross, W. C. J. The mode of production of chromosome abnormalities by nitrogen mustard: possible role of crosslinking. Nature (Lond.), 163: 667-669, 1949.
24. Ward, K , Jr. The chlorinated ethylamines: a new type of vesicant. J Am. Chem Soc., 57: 914-916, 1935.
25. Loveless, A., and Revell, S. New evidence on the mode of action of "mitotic poisons." Nature (Lond.), 164: 938-944, 1949.
26. Haddow, A., Kon, G. A. R., and Ross, W. C. J Effects upon tumors of various haloalkylarylamines Nature (Lond), 162: 824-825, 1948
27. Burchenal, J. H., and Riley, J. B Nitrogen mustards, the relationship between chemical structure and chemotherapeutic activity. Cancer Res., 9: 553-554, 1949.
28. Marmur, J , and Doty, P. Heterogeneity in DNA. Nature (Lond.), 183: 1427-1429, 1959.
29. Doty, P., Marmur, J., Eigner, J., and Schildkraut, C. Strand separation and specific recombination in DNA: physical chemical studies. Proc. Natl. Acad. Sci. USA, 46, 461-476, 1960.
30. Kohn, K. W., Spears, C. L , and Doty, P. Inter-strand crosslinking of DNA by nitrogen mustard J. Mol. Biol., 19: 266-288, 1966.
31. Kohn, K W., Steigbigel, N. H., and Spears, C. L Crosslinkmg and repair of DNA in sensitive and resistant strains of E. coli treated with nitrogen mustard. Proc. Natl. Acad. Sci USA, 53: 1154-1161, 1965
32. Brookes, P., and Lawley, P. D. Reaction of mustard gas with nucleic acids in vitro and in vivo. Biochem. J , 77: 478-484, 1960.
33. Brookes, P , and Lawley, P D The alkylation of guanosine and guanylic acid. J. Chem Soc., 1961: 3923-3928, 1961.
34. Iyer, V. N., and Szybalski, W. A molecular mechanism of mitomycin action linking of complementary DNA strands. Proc Natl. Acad Sci USA, 50: 355-362, 1963.
35. Roberts, J J., and Pascoe, J M. Crosslinking of complementary strands of DNA in mammalian cells by antitumor platinum compounds. Nature (Lond ), 235: 282-284, 1971.
36. Kohn, K. W. Interstrand cross-linking of DNA by 1,3-bis(2-chloroethyl)-1-nitrosourea and other 1-(2-haloethyl)-1-nitrosoureas. Cancer Res , 37: 1450-1454, 1977.
37. Kohn, K W , and Ewig, R A Alkaline elution analysis, a new approach to the study of DNA single-strand interruptions in cells. Cancer Res., 33: 1849-1853, 1973.
38. Kohn, K. W DNA as a target in cancer chemotherapy: measurement of macromolecular DNA damage produced in mammalian cells by anticancer agents and carcinogens. Methods Cancer Res , 16: 291-345, 1979
39. Kohn, K. W., Ewig, R A., Erickson, L. C., and Zwelling, L. A. Measurement of strand breaks and crosslinks in DNA by alkaline elution. In: E C. Friedberg and P. C Hanawalt (eds ), DNA Repair A Laboratory Manual of Research Techniques, pp. 379-401 New York: Marcel Dekker, 1981.
40. Kohn, K W. The significance of DNA damage assays in toxicity and carcinogenicity assessment Ann NY Acad. Sci., 407 106-118, 1983.
41. Kohn, K. W. DNA filter elution methods in anticancer drug development. Cancer Treat Res , 36: 3-38, 1987.
42. Kohn, K W Principles and practice of DNA filter elution. Pharmacol. Ther., 49: 55-77, 1991
43. Bradley, M. O., and Kohn, K. W. X-ray induced DNA double strand break production and repair in mammalian cells as measured by neutral filter elution. Nucleic Acids Res., 7: 793-804, 1979.
44. Fornace, A. J , Jr. Measurement of M. luteus endonuclease sensitive lesions by alkaline elution. Mutat. Res , 94 263-276, 1982.
45. Kohn, K. W., and Ewig, R. A. DNA-protein crosslinking by trans-platinum(II)diamminedichloride in mammalian cells, a new method of analysis. Biochim Biophys. Acta, 562: 32-40, 1979.
46. Ross, W. E., Glaubiger, D. L., and Kohn, K. W. Protein-associated DNA breaks in cells treated with adriamycin or ellipticine. Biochim. Biophys. Acta, 519: 23-30, 1978
47. Ross, W. E., Glaubiger, D., and Kohn, K. W. Qualitative and quantitative aspects of intercalator-mduced DNA strand breaks. Biochim. Biophys. Acta, 562: 41-50, 1979.
48. Kohn, K. W., Erickson, L. C., Ewig, R. A., and Friedman, C A. Fractionation of DNA from mammalian cells by alkaline elution. Biochemistry, 15: 4629-4637, 1976
49. Fornace, A. J. J., Kohn, K. W., and Kann, H. E. J DNA single-strand breaks during repair of UV damage in human fibroblasts and abnormalities of repair in xeroderma pigmentosum. Proc. Natl. Acad. Sci USA, 73: 39-43, 1976.
50. Fornace, A. J., Jr., and Kohn, K. W DNA-protein cross-linking by ultraviolet radiation in normal human and xeroderma pigmentosum fibroblasts. Biochim. Biophys. Acta, 435: 95-103, 1976
51. Ewig, R. A , and Kohn, K W DNA damage and repair in mouse leukemia L1210 cells treated with nitrogen mustard, 1,3-bis (2-chloroethyl)-1-nitrosourea, and other nitrosoureas. Cancer Res., 37: 2114-2122, 1977.
52. Ross, W. E , Ewig, R A., and Kohn, K W Differences between melphalan and nitrogen mustard in the formation and removal of DNA cross-links. Cancer Res., 38: 1502-1506, 1978.
53. Zwelling, L A., Filipski, J., and Kohn, K. W Effect of thiourea on survival and DNA crosslink formation in cells treated with platinum(II) complexes, L-phenylalanine mustard, and Bis(2-chloroethyl)methylamine Cancer Res, 39: 4989-4995, 1979.
54. Erickson, L. C., Ramonas, L. M , Zaharko, D. S., and Kohn, K W. Cytotoxicity and DNA crosslinking activity of 4-sulfidocyclophosphamides in mouse leukemia cells. Cancer Res., 40: 4216-4220, 1980
55. Ducore, J. M , Erickson, L C., Zwelling, L. A., Laurent, G., and Kohn, K. W. Comparative studies of DNA crosslinking and cytotoxicity in Burkitt's lymphoma cell lines treated with cid-diamminedichloroplatinum(II) and L-phenylalanine mustard Cancer Res , 42: 897-902, 1982.
56. Sanban, E., Kohn, K. W , Zlotogorski, C , Laurent, G., D'Incalci, M., Day, R., Smith, B. H., Kornblith, P. L., and Erickson, L. C. DNA cross-linking responses of human malignant glioma cell strains to chloroethylnitrosoureas, cisplatin, and diaziquone. Cancer Res , 47 3988-3994, 1987.
57. Zwelling, L. A., Kohn, K W., Ross, W. E., Ewig, R. A., and Anderson, T. Kinetics of formation and disappearance of a DNA cross-linking effect in mouse leukemia L1210 cells treated with cis- and trans-diamminedichloroplatinum(II). Cancer Res., 38, 1762-1768, 1978.
58. Zwelling, L. A , Anderson, T , and Kohn, K. W DNA-protein and DNA interstrand crosslinking by cis- and trans-platinum(II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res , 39 365-369, 1979
59. Zwelling, L. A , Bradley, M. O., Sharkey, N A., Anderson, T., and Kohn, K. W Mutagenicity, cytotoxicity and DNA crosslinking in V79 Chinese hamster cells treated with cis- and trans-Pt(II)diammindichloride Mutat. Res , 67: 271-280, 1979
60. Erickson, L C., Zwelling, L. A., Ducore, J. M., Sharkey, N. A., and Kohn, K W Differential cytotoxicity and DNA crosslinking in normal and transformed human fibroblasts treated with cis-diamminedichloroplatinum(II). Cancer Res., 41: 2791-2794, 1981.
61. Laurent, G., Erickson, L C., Sharkey, N A , and Kohn, K W. DNA crosslinking and cytotoxicity induced by cis-diammineplatinum(II) in human normal and tumor cell lines. Cancer Res , 41 3347-3351, 1981
62. Micetich, K., Zwelling, L. A., and Kohn, K W Quenching of DNA platinum(II) monoadducts as a possible mechanism of resistance to cis-diamminedichloroplatinum(II) in L1210 cells. Cancer Res , 43: 3609-3613, 1983
63. Cohen, L. F., Ewig, R. A., Kohn, K. W , and Glaubiger, D. Interstrand DNA crosslinking by 4,5′,8-trimethylpsoralen plus monochromatic ultraviolet light. Studies by alkaline elution in mouse L1210 leukemia cells. Biochim. Biophys Acta, 610 56-63, 1980.
64. Ewig, R. A , and Kohn, K. W DNA-protein cross-linking and DNA interstrand cross-linking by haloethylnitrosoureas in L1210 cells Cancer Res , 38: 3197-3203, 1978.
65. Erickson, L. C , Laurent, G., Sharkey, N A., and Kohn, K. W DNA crosslinking and monoadduct repair in nitrosourea-treated human tumor cells. Nature (Lond.), 288: 727-729, 1980.
66. Erickson, L. C., Bradley, M. O , and Kohn, K W. Measurements of DNA damage in Chinese hamster cells treated with equitoxic and equimutagenic doses of nitrosoureas Cancer Res., 38: 3379-3384, 1978.
67. Erickson, L. C., Bradley, M. O., Ducore, J. M , Ewig, R. A., and Kohn, K. W. DNA crosslinking and cytotoxicity in normal and transformed human cells treated with antitumor nitrosoureas. Proc. Natl. Acad. Sci. USA., 77: 467-471, 1980
68. Kohn, K. W. Prospects for improved chloroethylnitrosoureas and related haloethylating agents. In: P. L. Kornblith and M. D. Walker (eds.), Advances in Neuro-Oncology, pp. 491-513. Mount Kisco, NY: Futura Publishing Co., Inc., 1988.
69. Gibson, N. W., Erickson, L. C., and Kohn, K W. DNA damage and differential cytotoxicity produced in human cells by 2-chloroethyl(methylsulfonyl)-methanesulfonate, a new DNA chloroethylating agent. Cancer Res., 45: 1674-1679, 1985.
70. Sariban, E., Erickson, L. C., and Kohn, K W. Effects of carbamoylation on cell survival and DNA repair in normal human embryo cells treated with various I-(2-chloroethyl)-1-nitrosoureas. Cancer Res., 44: 1352-1357, 1984
71. Wang, J. C. Interaction between DNA and an Escherichia coli protein omega. J. Mol. Biol., 55: 523-533, 1971
72. Blair, D. G., and Helinski, D. R. Relaxation complexes of plasmid DNA and protein. I. Strand-specific association of protein and DNA in the relaxed complexes of plasmids ColE1 and ColE2 J. Biol. Chem , 250: 8785-8789, 1975.
73. Champoux, J. J., and Dulbecco, R. An activity from mammalian cells that untwists superhelical DNA: a possible swivel for DNA replication. Proc Natl. Acad Sci. USA, 69: 143-146, 1972
74. Champoux, J. J Strand breakage by the DNA untwisting enzyme results in covalent attachment of enzyme to DNA. Proc. Natl. Acad. Sci. USA, 74: 3800-3804, 1977.
75. Zwelling, L. A., Michaels, S , Erickson, L. C , Ungerleiter, R. S , Nichols, M , and Kohn, K. W. Protein-associated DNA strand breaks in L1210 cells treated with the DNA intercalating agents amsacrine and adriamycin. Biochemistry, 20: 6553-6563, 1981.
76. Zwelling, L. A., Michaels, S., Kerrigan, D., Pommier, Y., and Kohn, K. W. Protein-associated DNA strand breaks produced in mouse leukemia L1210 cells by ellipticine and 2-methyl-9-hydroxyellipticinium. Biochem Pharmacol., 31: 3261-3267, 1982
77. Zwelling, L. A., Kerrigan, D , and Michaels, S. Cytotoxicity and DNA strand breaks by 5-iminodaunorubicin in mouse leukemia cells Cancer Res., 42: 2687-2691, 1982.
78. Pommier, Y., Covey, J., Kemgan, D , Mattes, W., Markovits, J., and Kohn, K W Role of DNA intercalation in the inhibition of purified mouse DNA topoisomerase II by 9-aminoacridines. Biochem. Pharmacol., 36: 3477-3486, 1987.
79. Filipski, J., and Kohn, K. W. Ellipticine-induced protein-associated DNA breaks in isolated 11210 nuclei. Biochim. Biophys Acta, 698 280-286, 1982
80. Pommier, Y., Schwartz, R E , Kohn, K. W., and Zwelling, L. A. Formation and rejoining of DNA double-strand breaks induced in isolated cell nuclei by antineoplastic intercalating agents. Biochemistry, 23 3194-3201, 1984.
81. Glisson, B S., Smallwood, S E., and Ross, W. E. Characterization of VP-16-induced DNA damage in isolated nuclei from L1210 cells Biochim. Biophys. Acta, 783: 74-79, 1984.
82. Covey, J. M., Kohn, K. W., Kerrigan, D , Tilchen, E. J., and Pommier, Y Topoisomerase H-mediated DNA damage produced by 4′-(9-acridinylamino)-methanesulfon-m-anisidide and related acridines in L1210 cells and isolated nuclei: relation to cytotoxicity. Cancer Res., 48: 860-865, 1988
83. Filipski, J , Yin, J., and Kohn, K. W. Reconstitution of intercalator-induced DNA scission by an active component from nuclear extracts. Biochim. Biophys. Acta, 741: 116-122, 1983
84. Liu, L F., Liu, C C., and Alberts, B. M. Type II DNA topoisomerases. Enzymes that can unknot a topologically knotted DNA molecule via a reversible double-strand break Cell, 79: 697-707, 1980
85. Liu, L F., Rowe, T. C , Yang, L , Tewey, K. M , and Chen, G. L. Cleavage of DNA by mammalian DNA topoisomerase II. J Biol. Chem., 258: 15365-15370, 1983
86. Tewey, K M , Rowe, T C., Yang, L , Halligan, B. D., and Liu, L. F. Adriamycin-induced DNA damage is mediated mammalian DNA topoisomerase II Science (Washington DC), 220: 466-468, 1984.
87. Tewey, K. M., Chen, G. L , Nelson, E. M., and Liu, L. F Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem. 259 9182-9187, 1984
88. Nelson, E. M., Tewey, K. M , and Liu, L F Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by amsacrine. Proc. Natl. Acad Sci USA, 81: 1361-1365, 1984.
89. Minford, J , Pommier, Y , Filipski, J., Kohn, K. W , Kerrigan, D., Mattern, M., Michaels, S., Schwartz, R., and Zwelling, L. A. Isolation of intercalator-dependent protein-linked DNA strand cleavage activity from cell nuclei and identification as topoisomerase II. Biochemistry, 25: 9-16, 1986
90. Ross, W E., Rowe, T. C . Glisson, B S , Yalowich, J , and Liu, L F. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res., 44: 5857-5860, 1984.
91. Rowe, T. C., Kupfer, G., and Ross, W. E. Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA cleavage. Biochem Pharmacol , 34: 2483-2487, 1985
92. Long, B. H., Musial, S. T., and Brattam, M. G. Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. Cancer Res., 45 3106-3112, 1985.
93. Long, B. H., Musial, S T , and Brattain, M G. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide. Cancer Res., 46: 3809-3816, 1986
94. Kerrigan, D , Pommier, Y., and Kohn, K. W Protein-linked DNA strand breaks produced by etoposide and teniposide in Mouse L1210 and Human VA-13 and HT-29 cell lines: relationship to cytotoxicity. NCI Monogr., 4: 117-121, 1987.
95. Long, B. H , Musial, S. T., and Brattain, M. G. Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM-26: a quantitative structure-activity relationship. Biochemistry, 23: 1183-1188, 1984
96. Liu, S-Y , Hwang, B-D., Haruna, M., Imakura, Y , Lee, K-H , and Cheng, Y-C. Podophyllotoxin analogs effects on DNA topoisomerase II, tubulin polymerization human KB cells, and their VP-16-resistant variants Mol. Pharmacol., 36: 78-82, 1989
97. Chang, J-Y., Han, F-S., Liu, S-Y., Wang, Z-Q., Lee, K-H., and Cheng, Y-C Effect of 4b-arylamino derivatives of 4′-O-demethylepipodophyllotoxin on human DNA topoisomerase II, tubulin polymerization, KB cells, and their resistant variants. Cancer Res , 51: 1755-1759, 1991
98. Pommier, Y , Tanizawa, A., and Kohn, K. W. Mechanisms of topoisomerase I inhibition by anticancer drugs. Adv Pharmacol., 29B: 73-91, 1994
99. Gupta, M., Fujimori, A., and Pommier, Y. Eukaryotic DNA topoisomerases I. Biochim. Biophys. Acta, 1262: 1-14, 1995
100. Wall, M. E., and Wani, M. C. Camptothecin and taxol: discovery so clinic - thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res , 55: 753-760, 1995.
101. Horwitz, M. S., and Horwitz, S. B. Intracellular degradation of HeLa and adenovirus type 2 DNA induced by camptothecin. Biochem. Biophys. Res. Commun., 45: 723-727, 1971.
102. Hsiang, Y H., Hertzberg, R , Hecht, S., and Liu, L. F Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol Chem., 260: 14873-14878, 1985.
103. Jaxel, C , Kohn, K W., and Pommier, Y. Topoisomerase I interaction with SV40 DNA in the presence and absence of camptothecin. Nucleic Acids Res., 16: 11157-11170, 1988.
104. Covey, J. M., Jaxel, C., Kohn, K. W., and Pommier, Y. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res., 49: 5016-5022, 1989.
105. Andoh, T , Ishii, K., Suzuki, Y., Ikegami, Y., Kusunoki, Y., Takemoto, Y., and Okada, K. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerae I Proc. Natl. Acad Sci USA, 84: 5565-5569, 1987.
106. Kjeldsen, E., Bonven, B. J., Andoh, T , Ishii, K., Okada, K , Bolund, L , and Westergaard, O. Characterization of a camptothecin-resistant human DNA topoisomerase I J. Biol. Chem., 263: 3912-3916, 1988.
107. Gupta, R S., Gupta, R , Eng, B., Lock, R. B., Ross, W. E., Hertzberg, R. P., Caranfa, M. J , and Johnson, R K Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res., 48, 6404-6410, 1988.
108. Sullivan, D. M., Latham, M. D., Rowe, T. C., and Ross, W. E. Purification and characterization of an altered topoisomerase II from a drug-resistant Chinese hamster ovary cell line. Biochemistry, 28, 5680-5687, 1989
109. Tamura, H., Kohchi, C , Yamada, R., Ikeda, T., Koiwai, O , Patterson, E., Keene, J. D , Okada, K , Kjeldsen, E., Nishikawa, K., and Andoh, T. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites Nucleic Acids Res., 19: 69-75, 1991.
110. Tanizawa, A., and Pommier, Y. Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture Cancer Res., 52: 1848-1854, 1992.
111. Tanizawa, A , Bertrand, R., Kohlhagen, G , Tabuchi, A., Jenkins, J., and Pommier, Y. Cloning of Chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance. J. Biol. Chem , 268: 25463-25468, 1993.
112. Fujimori, A., Harker, G., Kohlhagen, G., Hoki, Y , and Pommier, Y Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to Camptothecin Cancer Res., 55: 1339-1346, 1995.
113. Pommier, Y , Capranico, G., Orr, A., and Kohn, K W. Distribution of topoisomerase II cleavage sites in SV40 DNA and effects of drugs. J Mol. Biol., 222: 909-924, 1991.
114. Wasserman, K., Markovits, J , Jaxel, C , Capranico, G., Kohn, K. W., and Pommier, Y Effects of morpholinyldoxorubicin, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II Mol Pharmacol., 38 38-45, 1990.
115. Capranico, G., Jaxel, C., Roberge, M., Kohn, K. W., and Pommier, Y Nucleosome positioning as a critical determinant for the DNA cleavage sites of mammalian DNA topoisomerase II in reconstituted SV40 chromatin Nucleic Acids Res , 18: 4553-4559, 1990.
116. Pommier, Y , Cockenll, P. N , Kohn, K W., and Garrard, W T. Identification within the SV40 genome of a chromosomal loop attachment site that contains topoisomerase II cleavage sites J. Virol., 64: 419-423, 1990.
117. Riou, J-F., Lefevre, D , and Riou, G Stimulation of the topoisomerase II induced DNA cleavage sites in the c-myc gene by antitumor drugs is associated with gene expression Biochemistry, 28: 9104-9110, 1989.
118. Pommier, Y., Orr, A , Kohn, K. W , and Riou, J F Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene. Cancer Res., 52: 3125-3130, 1992.
119. Stewart, A. F, and Schutz, G Camptothecin-induced in vivo topoisomerase I cleavages in the transcriptionally active tyrosine aminotransferase gene Cell, 50: 1109-1117, 1987
120. Culotta, V , and Sollner-Webb, B. Sites of topoisomerase I action on X laevis ribosomal chromatin transcriptionally active rDNA has an ∼200 bp repeating structure. Cell, 52: 585-597, 1988.
121. Pommier, Y., Capranico, G., Orr, A , and Kohn, K. W. Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide Nucleic Acids Res., 19: 5973-5980, 1991.
122. Capranico, G , Zunino, F , Kohn, K. W., and Pommier, Y. Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity. Biochemistry, 29: 562-569, 1990.
123. Jaxel, C., Capranico, G., Kerrigan, D., Kohn, K W., and Pommier, Y. Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J. Biol. Chem., 266: 20418-20423, 1991.
124. Tanizawa, A., Kohn, K. W., and Pommier, Y. Induction of cleavage in topoisomerase I cDNA by topoisomerase I enzymes from calf thymus and wheat germ in the presence and absence of camptothecin. Nucleic Acids Res., 21: 5157-5166, 1993.
125. Jaxel, C., Kohn, K. W , Wani, M. C., Wall, M E., and Pommier, Y Structureactivity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity Cancer Res., 49: 1465-1469, 1989.
126. Leteurtre, F., Fesen, M., Kohlhagen, G., Kohn, K. W., and Pommier, Y. Specific interaction of camptothecin, a topoisomerase I inhibitor, with guanine residues of DNA detected by photoactivation at 365 nm. Biochemistry, 32: 8955-8962, 1993.
127. Pommier, Y., Kohlhagen, G., Kohn, K. W., Leteurtre, F., Wani, M. C., and Wall, M. E. Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. Proc. Natl. Acad. Sci. USA, 92: 8861-8865, 1995.
128. 7 alkylation by nitrogen mustards. Nucleic Acids Res., 14: 2971-2987, 1986.
129. 7 positions by nitrogen mustards. Nucleic Acids Res., 15: 10531-10549, 1987.
130. Mattes, W B , Hartley, J. A., and Kohn, K. W GC-rich regions in genomes as targets for DNA alkylation Carcinogenesis (Lond.), 9: 2065-2072, 1988.
131. Kohn, K. W., Orr, A., O'Connor, P. M., Guziec, L. J , and Guziek, F. S., Jr Synthesis and DNA-sequence selectivity of a series of mono and difunctional 9-aminoacridine nitrogen mustards. J. Med. Chem , 37: 67-72, 1994.
132. Creech, H. J., Preston, R. K. Peck, R M , O'Connell, A. P., and Ames B. N. Antitumor and mutagenic properties of a variety of heterocyclic nitrogen and sulfur mustards. J. Med. Chem., 15: 739-746, 1972
133. Markovits, J., Pommier, Y., Kerrigan, D , Covey, J , Tilchen, E. J , and Kohn, K. W Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH3T3 fibroblasts and L1210 leukemia cells. Cancer Res., 47: 2050-2055, 1987.
134. Kaufmann, S. H. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res., 51: 1129-1136, 1991
135. O'Connor, P. M , Nieves-Neira, W., Kerrigan, D., Bertrand, R., Goldman, J , Kohn, K. W., and Pommier, Y. S-phase population does not correlate with the cytotoxicity of camptothecin and 10,11-methylenedioxycamptothecin in human colon carcinoma HT-29 cells Cancer Commun., 3: 233-240, 1991
136. Hsiang, Y , Liu, L. F , Wall, M. E , Wani, M. C , Nicholas, A W., Mamkumar, G., Kirschenbaum, S., Silber, R., and Potmesil, M. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res., 49: 4385-4389, 1989
137. O'Connor, P. M., Kerrigan, D., Bertrand, R., Kohn, K. W , and Pommier, Y. 10,11-Methylenedioxycamptothecin, a topoisomerase I inhibitor of increased potency: DNA damage and correlation to cytotoxicity in human colon carcinoma (HT-29) cells Cancer Commun , 2: 395-400, 1990.
138. Potmesil, M. Camptothecins: from bench research to hospital wards. Cancer Res., 54: 1431-1439, 1994.
139. Hertzberg, R P., Caranfa, M. J., and Hecht, S. M. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry, 28: 4629-4638, 1989.
140. Crow, R T , and Crothers, D. M. Structural Modifications of camptothecin and effects on topoisomerase I inhibition. J Med. Chem., 35: 4160-4164, 1992.
141. Hsiang, Y., Lihou, M. G., and Liu, L. F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res., 49, 5077-5082, 1989.
142. Holm, C , Covey, J. M., Kerrigan, D., and Pommier, Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells Cancer Res , 49: 6365-6368, 1989.
143. Zhang, H , D'Arpa, P , and Liu, L. F A model for tumor cell killing by topoisomerase poisons. Cancer Cells, 2: 23-27, 1990.
144. Avemann, K., Knippers, R., Koller, T., and Sogo, J. M. Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks. Mol. Cell. Biol , 8: 3026-3034, 1988
145. Pommier, Y , Leteurtre, F., Fesen, M R., Fujimori, A., Bertrand, R., Solary, E , Kohlhagen, G , and Kohn, K W. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors Cancer Invest., 12: 530-542, 1994.
146. Tanizawa, A , Kohn, K. W., Kohlhagen, G., Leteurtre, F , and Pommier, Y. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Biochemistry, 34: 7200-7206, 1995
147. Hartwell, L H., and Weinert, T A. Checkpoints: controls that ensure the order of cell cycle events. Science (Washington DC), 246: 629-643, 1989.
148. Hartwell, L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells Cell, 71: 543-546, 1992
149. Murray, A W Creative blocks: cell-cycle checkpoints and feedback controls. Nature (Lond ), 359: 599-604, 1992.
150. 2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently J. Biol Chem., 268 8298-8308, 1993
151. O'Connor, P M., and Kohn, K. W. A fundamental role for cell cycle regulation in the chemosensitivity of cancer cells? Semin Cancer Biol , 3: 409-416, 1992.
152. Kohn, K W , Jackman, J., and O'Connor, P M. Cell cycle control and cancer chemotherapy J. Cell. Biochem , 54: 440-452, 1994.
153. Lau, C. C., and Pardee, A. B Mechanism by which caffeine potentiates lethality of nitrogen mustard Proc. Natl. Acad Sci. USA, 79: 2942-2946, 1982.
154. Fingert, H. J., Chang, J D , and Pardee, A. B. Cytotoxic, cell cycle, and chromosomal effects of methylxanthines in human tumor cells treated with alkylating agents Cancer Res., 46: 2463-2467, 1986.
155. Fingert, H. J., Pu, A. T., Chen, Z. Y., Googe, P. B., Alley, M. C., and Pardee, A. B. In vivo and in vitro enhanced antitumor effects by pentoxifylline in human cancer cells treated with thiotepa. Cancer Res., 48: 4375-4381, 1988.
156. Teicher, B A., Holden, S. A , Herman, T. S., Epelbaum, U., Pardee, A. B., and Dezube, B. Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo. Anticancer Res., 11: 1555-1560, 1991.
157. Fan, S , Smith, M. L , Rivet, D. J., Duba, D., Zhan, Q., Kohn, K. W., Fornace, A. J., Jr., and O'Connor, P M. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline Cancer Res , 55: 1649-1654, 1995.
158. 2 checkpoint function in cancer cells with disrupted p53. J. Natl Cancer Inst., 88 956-963, 1996.
159. Lock, R. B. Inhibition of p34cdc2 kinase activation, p34cdc2 tyrosine dephosphorylation, and mitotic progression in Chinese hamster ovary cells exposed to etoposide Cancer Res , 52: 1817-1822, 1992.
160. 2 arrest: altered regulation of p34cdc2/cyclin B. Cancer Res., 52: 1823-1829, 1992.
161. 2 block induced by ionizing radiation. Cancer Res , 51: 5113-5117, 1991.
162. Muschel, R. J., Zhang, H. B., and McKenna, W. G. Differential effect of ionizing radiation on the expression of cyclin A and cyclin B in HeLa cells. Cancer Res., 53 1128-1135, 1993.
163. 2 arrest induced by nitrogen mustard. Proc Natl. Acad Sci USA, 91 9480-9484, 1994.
164. O'Connor, P. M., and Fan, S DNA damage checkpoints: implications for cancer therapy Prog. Cell Cycle Res., 2: 1-9, 1996.
165. Kastan, M B. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
166. Kuerbitz, S J., Plunkett, B. S., Walsh, W V , and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation Proc. Natl Acad. Sci. USA, 89: 7491-7495, 1992
167. 1 cyclins. Cell. 73: 1059-1065, 1993.
168. 1 phase progression: cycling on cue. Cell, 79: 551-555, 1994.
169. Morgan, D O Principles of CDK regulation. Nature (Lond ), 374: 131-134, 1995.
170. Levine, A , Momand, J., and Finlay, C. A. The p53 tumor suppressor gene. Nature (Lond ), 351 453-456, 1991
171. Hollstein, M., Sidransky, D., Vogelstein, B , and Harris, C. C p53 mutations in human cancers Science (Washington DC), 251: 49-53, 1991
172. Stone, S , Dayananth, P., and Kamb, A. Reversible, p16-mediated cell cycle arrest as protection from chemotherapy. Cancer Res., 56: 3199-3202, 1996
173. Lowe, S W., Ruley, H. E., Jacks, T , and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents Cell, 74: 957-967, 1993.
174. Lowe, S. W. Cancer therapy and p53. Curr. Opin. Oncol., 7: 547-553, 1995.
175. Hawkins, D S., Demers, G. W , and Galloway, D. A. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic age. Cancer Res., 56: 892-898, 1996.
176. Canman, C. E., Gilmer, T. M , Coutts, S. B., and Kastan, M. B. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev , 9: 600-611, 1995
177. Smith, M L., and Fornace, A. J., Jr. The two faces of tumor suppressor p53. Am. J. Pathol., 148: 1019-1022, 1996.
178. Polyak, K , Waldman, T , He, T-C., Kinzler, K. W., and Vogelstein, B. Genetic determinants of p53-induced apoptosis and growth arrest Genes Dev , 10: 1945-1952, 1996.
179. Fan, S , el-Deiry, W S., Bae, I , Freeman, J , Jondle, D , Bhatia, K , Fornace, A. J , Jr., Magrath, I. Kohn, K. W , and O'Connor, P M p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res , 54: 5824-5830, 1994.
180. O'Connor, P. M , Jackman, J., Jondle, D., Bhatia, K , Magrath, I., and Kohn, K W Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines Cancer Res., 53 4776-4780, 1993
181. Smith, M. L., Chen, I. T , Zhan, Q., O'Connor, P. M , and Fornace, A. J., Jr. Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage. Oncogene, 10: 1053-1059, 1995
182. Smith, M. L., Udo Kontny, H., Zhan, Q , Sreenath, A , O'Connor, P. M., and Fomace, A J., Jr. Antisense GADD45 expression results in decreased DNA repair and sensitizes cells to u.v.-irradiation or cisplatin. Oncogene, 13: in press, 1996.
183. Smith, M. L., and Fornace, A J., Jr. Genomic instability and the role of p53 mutations in cancer cells. Curr. Opin. Oncol., 7: 69-75, 1995.
184. Zambetti, G. P., and Levine, A. J. A comparison of the biological activities of wild-type and mutant p53. FASEB J., 7: 855-865, 1993.
185. Ko, L. J., and Prives, C p53: puzzle and paradigm Genes Dev., 10: 1054-1072, 1996.
186. Kastan, M B , Zhan, Q , El-Deiry, W S , Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B , and Fornace, A. J J A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71: 587-597, 1992.
187. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D , Mercer, W. E., Kinzler, K. W., and Vogelstein, B WAF1, a potential mediator of p53 tumor suppression Cell, 75: 817-825, 1993.
188. 1 arrest and apoptosis. Cancer Res., 54, 1169-1174, 1994.
189. Miyashita, T., Krajewski, S., Krajewska, M., Wang, H. G., Lin, H. K., Liebermann, D. A., Hoffman, B., and Reed, J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and vivo. Oncogene, 9: 1799-1805, 1994.
190. Miyashita, T., and Reed, J. C. Tumor suppressor p53 is a direct transcriptional activator of the human box gene Cell, 80: 293-299, 1995.
191. Zhan, Q., Fan, S , Bae, I , Guiliouf, C., Liebermann, D. A., O'Connor, P. M , and Fornace, A J., Jr Induction of bax by genotoxic stress in human cells correlates with normal status and apoptosis [published erratum appears in Oncogene, 10: 1259, 1995]. Oncogene, 9: 3743-3751, 1994.
192. Wu, X., and Levine, A. J. p53 and E2F-1 cooperate to mediate apoptosis. Proc. Natl. Acad. Sci. USA, 91: 3602-3606, 1994.
193. Kessis, T., Slebos, R J., Nelson, W. G., Kastan, M. B., Plunkett, B. S., Han, S. M., Lorincz, A. T , Hedrick, L., and Cho, K. R Human papillomavirus 16 E6 expression disrupt the p53 mediated cellular response to DNA damage. Proc. Natl. Acad. Sci. USA, 90: 3988-3992, 1993
194. Monks, A , Scudiero, D., Skehan, P , Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vigro-Wolff, A., et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst., 83: 757-766, 1991
195. Paull, K. D , Shoemaker, R. H., Hodes, L , Monks, A , Scudiero, D. A., Rubinstein, L , Plowman, J., and Boyd, M. R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst , 81 1088-1092, 1989.
196. Weinstein, J. N , Kohn, K W , Grever, M R , Viswanadhan, V. N., Rubinstein, L. V., Monks, A P., Scudiero, D. A., Welch, L., Koutsoukos, A. D., Chiausa, A. J., and Paull, K. D. Neural computing in cancer drug development, predicting mechanism of action. Science (Washington DC), 258: 447-451, 1992.
197. van Osdol, W. W., Myers, T G , Paull, K D., Kohn, K. W , and Weinstein, J. N. Use of the Kohonen self-organizing map to study the mechanisms of action chemother-apeutic agents. J. Natl. Cancer Inst , 86: 1853-1859, 1994.
198. Weinstein, J. N., Myers, T., Buolamwini, J., Raghavan, K , Viswanadhan, V N., Licht, J., Rubinstein, L V , Koutsoukos, A. K., Kohn, K. W., Zaharevitz, D , Grever, M. R., Monks, M R., Scudiero, K. A., Chabner, B A , Anderson, N. L., and Paull, K. D. Predictive statistics and artificial intelligence in the U. S. National Cancer Institute's drug discovery program for cancer and AIDS. Stem Cells, 12: 13-22, 1994
199. Weinstein, J. N., Myers, T. G., O'Connor, P M., Friend, S. H., Fornace, A. J., Jr., Kohn, K W., Fojo, R , Bates, S E., Rubinstein, L. V., Anderson, N. L , Buolomwini, J K., van Osdol, W. W , Monks, A. P., Scudiero, D. A., Sausville, E. A , Zaharevitz, D. W , Bunow, B., Johnson, G. S , Wittes, R. E., and Paull, K. D. An information-intensive approach to the molecular pharmacology of cancer. Science (Washington DC), in press, 1997
200. Koutsoukos, A D., Rubinstein, L. V., Faraggi, D , Kalyandrug, S., Weinstein, J. N , Paull, K. D , Kohn, K. W , and Simon, R. M. Discrimination techniques applied to the NCI in vitro antitumor drug screen: predicting biochemical mechanism of action. Stat. Med., 13: 719-730, 1994
201. Lefebure, V. The Riddle of the Rhine Chemical Strategy in Peace and War, p. 282, New York: Chemical Foundation, Inc , 1923
202. Cain, B. F., Atwell, G. J., and Seelye, R. N. Potential antitumour agents. 11 9-amlinoacridines. J. Med Chem., 14: 311-315, 1971.
203. Cain, B. F , and Atwell, G. J. The experimental antitumour properties of three congeners of the acridylmethanesulphonanilide (AMSA) series. Eur J. Cancer., 10: 539-549, 1974.
204. Smith, M. L. Zhan, Q., Bae, I., and Fornace, A J , Jr. Role of retinoblastoma gene product in p53-mediated DNA damage response Exp. Cell Res , 215: 386-389, 1994.
205. Smith, M. L , and Fornace, A. J , Jr Mammalian DNA damage-inducible genes associated with growth arrest and apoptosis. Mutat. Res., 340 109-124, 1996.